Page last updated: 2024-08-26

fulvestrant and Carcinoma, Lobular

fulvestrant has been researched along with Carcinoma, Lobular in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (40.00)	29.6817
2010's	4 (40.00)	24.3611
2020's	2 (20.00)	2.80

Authors

Authors	Studies
Anan, K; Aogi, K; Fujisawa, T; Hasegawa, Y; Hattori, M; Ito, Y; Kawaguchi, H; Masuda, N; Morita, S; Nakamura, S; Nakayama, T; Ohno, S; Ohtani, S; Saji, S; Sato, N; Takano, T; Toi, M; Tokunaga, E; Yamaguchi, M; Yamamoto, Y; Yamashita, H; Yamashita, T; Yotsumoto, D	1
Alchami, F; Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; Cox, C; Foxley, A; Howell, SJ; Joffe, J; Jones, RH; Madden, TA; Moon, S; Twelves, C; Venkitaraman, R; Waters, S	1
Baena-Cañada, JM; Bayo, JL; Blancas, I; Bofill, JS; Carabantes, F; Conde, V; Cruz, J; Esquerdo, G; Fontanillas, M; García-Palomo, A; Gordon, MM; Illarramendi, JJ; Jaen, A; Jáñez, NM; Lao, J; Martínez, E; Mendiola, C; Pérez-Ruiz, E; Ruiz-Borrego, M; Sotelo, MJ	1
Asmar, N; Barriere, J; Rey, JF; Sattonnet, C	1
Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M	1
Alran, S; Balleyguier, C; Becette, V; Bourgier, C; Boussion, V; Cherel, P; Kerbrat, P; Lavau-Denes, S; Lemonnier, J; Lerebours, F; Martin, AL; Mathieu, MC; Mouret-Fourme, E; Mouret-Reynier, MA; Nabholz, JM; Rivera, S; Salmon, R; Sigal, B; Thibault, F; Trassard, M; Venat-Bouvet, L	1
Cheung, KL; Rampaul, RS; Tang, JY	1
Alonso Muñoz, A; García Alfonso, P; Martínez Marín, V; Muñoz Martín, AJ; Pérez Manga, G; Viñuela Benéitez, MC	1
DiLeonardo, M; Gibbons, G; Resnik, KS	1
Altorjai, G; Bartsch, R; Gnant, M; Jakesz, R; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC	1

Trials

2 trial(s) available for fulvestrant and Carcinoma, Lobular

Article	Year
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. The Lancet. Oncology, 2020, Volume: 21, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate	2020
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial Cancer, 2016, Volume: 122, Issue:19 Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Female; Follow-Up Studies; France; Fulvestrant; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Survival Rate; Triazoles	2016

Article

Year

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.

The Lancet. Oncology, 2020, Volume: 21, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate

2020

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial

Cancer, 2016, Volume: 122, Issue:19

Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Female; Follow-Up Studies; France; Fulvestrant; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Survival Rate; Triazoles

2016

Other Studies

8 other study(ies) available for fulvestrant and Carcinoma, Lobular

Article	Year
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. Breast cancer (Tokyo, Japan), 2020, Volume: 27, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate	2020
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:7 Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Drug Resistance, Neoplasm; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Lymphatic Metastasis; Middle Aged; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies	2018
Gastric Metastasis Mimicking Linitis Plastica 20 Years after Primary Breast Cancer. A Case Report. Journal of gastrointestinal and liver diseases : JGLD, 2018, Volume: 27, Issue:4 Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Carcinoma, Lobular; Diagnosis, Differential; Female; Fulvestrant; Gastroscopy; GATA3 Transcription Factor; Humans; Immunohistochemistry; Linitis Plastica; Predictive Value of Tests; Stomach Neoplasms; Time Factors; Treatment Outcome	2018
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nature communications, 2016, Feb-09, Volume: 7 Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles	2016
The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma. World journal of surgical oncology, 2008, Dec-01, Volume: 6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Estradiol; Female; Fulvestrant; Humans; Intestinal Obstruction; Middle Aged; Neoplasm Metastasis	2008
[Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer]. Medicina clinica, 2009, Sep-19, Volume: 133, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Estrogen Antagonists; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Retrospective Studies; Time Factors; Treatment Outcome	2009
Clinically occult cutaneous metastases. Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:6 Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing	2006
Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-01, Volume: 13, Issue:15 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Prospective Studies; Receptor, ErbB-2; Receptors, Progesterone; Treatment Outcome	2007